Sirnaomics Ltd
02257
Company Profile
Business description
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group’s operations and non-current assets are located at the United States of America and the mainland of the People’s Republic of China.
Contact
No.218 Xinghu Street
Unit 415, A4 Building
Suzhou Industrial Park
Suzhou
CHNT: +86 51262956283
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
52
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,079.50 | 16.92 | 0.21% |
| DAX 40 | 24,610.95 | 92.17 | -0.37% |
| Dow JONES (US) | 48,940.34 | 451.75 | 0.93% |
| FTSE 100 | 10,150.52 | 23.74 | 0.23% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,158.12 | 203.80 | 0.89% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,857.11 | 60.25 | 0.89% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |